Cover Image
Market Research Report

Global Antihypertensive Drugs Market 2019-2023

Published by TechNavio (Infiniti Research Ltd.) Product code 806180
Published Content info 124 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Antihypertensive Drugs Market 2019-2023
Published: March 6, 2019 Content info: 124 Pages
Description

About this market

Patients with hypertension are generally treated with drugs that can reduce blood volume (reducing central venous pressure and cardiac output), reduce systemic vascular resistance, and reduce cardiac output by depressing heart rate and stroke volume. For instance, diuretic drugs decrease the blood volume by increasing urine output by the kidney. Similarly, vasodilator drugs dilate blood vessels through the relaxation of smooth muscle in blood vessels. Cardioinhibitory drugs depress cardiac function by decreasing heart rate, myocardial contractility, or both, which decreases cardiac output and arterial pressure. Hence, the availability of a wide range of therapeutics is offering specific treatment to the patients with hypertension and driving the growth of the global antihypertensive drugs market during the forecast period. Technavio's analysts have predicted that the antihypertensive drugs market will register a CAGR of over 2% by 2023.

Market Overview

Rising population with risk factors of hypertension

Some medical conditions can raise the risk of high blood pressure. The growing prevalence of diabetes increases the risk of development of hypertension. Hence, an increase in the number of people with these risk factors is expected to increase the number of people with hypertension. This, in turn, is expected to aid in the use of available drugs, which will drive the growth of the global antihypertensive drugs market during the forecast period.

Increasing generics popularity

Generic medicines contain the same active ingredient in the same quantity as a branded medicine. The development of generic drugs is simple and less time-taking. Therefore, the launch of generic drugs with lesser price than the innovator drugs is diluting and deceleration the market growth and is expected to hamper the growth of the market during our forecast period.

For the detailed list of factors that will drive and challenge the growth of the antihypertensive drugs market during the 2019-2023, view our report.

Competitive Landscape

The market appears to be moderately fragmented and with the presence of several vendors. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

Table of Contents
Product Code: IRTNTR30961

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
  • PART 06: PIPELINE

PART 07: MARKET SEGMENTATION BY TYPE

  • Market segmentation by type
  • Comparison by type
  • Systemic hypertension - Market size and forecast 2018-2023
  • Pulmonary hypertension - Market size and forecast 2018-2023
  • Market opportunity by type

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AstraZeneca
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations

List of Exhibits:

  • Exhibit 01: Global pharmaceuticals market
  • Exhibit 02: Segments of global pharmaceuticals market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Market definition - Inclusions and exclusions checklist
  • Exhibit 06: Market size 2018
  • Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 09: Five forces analysis 2018
  • Exhibit 10: Five forces analysis 2023
  • Exhibit 11: Bargaining power of buyers
  • Exhibit 12: Bargaining power of suppliers
  • Exhibit 13: Threat of new entrants
  • Exhibit 14: Threat of substitutes
  • Exhibit 15: Threat of rivalry
  • Exhibit 16: Market condition - Five forces 2018
  • Exhibit 17: Global antihypertensive drugs market pipeline: Overview
  • Exhibit 18: Phase III pipeline molecules: Overview
  • Exhibit 19: Type - Market share 2018-2023 (%)
  • Exhibit 20: Comparison by type
  • Exhibit 21: Systemic hypertension - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 22: Systemic hypertension - Year-over-year growth 2019-2023 (%)
  • Exhibit 23: Pulmonary hypertension - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 24: Some of the drugs available for treatment of pulmonary hypertension
  • Exhibit 25: Pulmonary hypertension - Year-over-year growth 2019-2023 (%)
  • Exhibit 26: Market opportunity by type
  • Exhibit 27: Customer landscape
  • Exhibit 28: Market share by geography 2018-2023 (%)
  • Exhibit 29: Geographic comparison
  • Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 31: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 32: Top 3 countries in North America
  • Exhibit 33: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 34: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 35: Top 3 countries in Europe
  • Exhibit 36: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 37: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 38: Top 3 countries in Asia
  • Exhibit 39: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 40: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 41: Top 3 countries in ROW
  • Exhibit 42: Key leading countries
  • Exhibit 43: Market opportunity
  • Exhibit 44: Available drugs for treatment of hypertension: Overview
  • Exhibit 45: Generic drugs that received approval from US FDA for treatment of hypertension since 2016: Overview
  • Exhibit 46: Impact of drivers and challenges
  • Exhibit 47: Vendor landscape
  • Exhibit 48: Landscape disruption
  • Exhibit 49: Vendors covered
  • Exhibit 50: Vendor classification
  • Exhibit 51: Market positioning of vendors
  • Exhibit 52: AstraZeneca - Vendor overview
  • Exhibit 53: AstraZeneca - Business segments
  • Exhibit 54: AstraZeneca - Organizational developments
  • Exhibit 55: AstraZeneca - Geographic focus
  • Exhibit 56: AstraZeneca - Key offerings
  • Exhibit 57: AstraZeneca - Key customers
  • Exhibit 58: Johnson & Johnson Services, Inc. - Vendor overview
  • Exhibit 59: Johnson & Johnson Services, Inc. - Business segments
  • Exhibit 60: Johnson & Johnson Services, Inc. - Organizational developments
  • Exhibit 61: Johnson & Johnson Services, Inc. - Geographic focus
  • Exhibit 62: Johnson & Johnson Services, Inc. - Segment focus
  • Exhibit 63: Johnson & Johnson Services, Inc. - Key offerings
  • Exhibit 64: Johnson & Johnson Services, Inc. - Key customers
  • Exhibit 65: Merck & Co., Inc. - Vendor overview
  • Exhibit 66: Merck & Co., Inc. - Business segments
  • Exhibit 67: Merck & Co., Inc. - Organizational developments
  • Exhibit 68: Merck & Co., Inc. - Geographic focus
  • Exhibit 69: Merck & Co., Inc. - Segment focus
  • Exhibit 70: Merck & Co., Inc. - Key offerings
  • Exhibit 71: Merck & Co., Inc. - Key customers
  • Exhibit 72: Novartis AG - Vendor overview
  • Exhibit 73: Novartis AG - Business segments
  • Exhibit 74: Novartis AG - Organizational developments
  • Exhibit 75: Novartis AG - Geographic focus
  • Exhibit 76: Novartis AG - Segment focus
  • Exhibit 77: Novartis AG - Key offerings
  • Exhibit 78: Novartis AG - Key customers
  • Exhibit 79: Pfizer Inc. - Vendor overview
  • Exhibit 80: Pfizer Inc. - Business segments
  • Exhibit 81: Pfizer Inc. - Organizational developments
  • Exhibit 82: Pfizer Inc. - Geographic focus
  • Exhibit 83: Pfizer Inc. - Segment focus
  • Exhibit 84: Pfizer Inc. - Key offerings
  • Exhibit 85: Pfizer Inc. - Key customers
  • Exhibit 86: Validation techniques employed for market sizing
  • Exhibit 87: List of abbreviations
Back to Top